Table 1.
Frequency and clinical consequences of recurrent gene mutations in patients with MDS
NA indicates not available.
*MDS/MPN indicates overlap syndromes per the World Health Organization (2008), including CMML-1/CMML-2; sAML, MDS-derived secondary AML. Mutation frequencies are based on studies that genotyped > 30 patients except MDS patients with RUNX1 mutations (n = 23) and all sAML frequencies (n > 20).
†Inconsistent impact on survival reported.
